title: Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.
abstract: Everolimus (Certican; Novartis Pharma AG, Basel, Switzerland) represents the latest generation of proliferation signal inhibitors (PSIs). Everolimus is indicated for use as an immunosuppressive drug in renal and heart transplantation. This report reflects the recommendations of the second German-Austrian Certican Consensus Conference, held in January 2006, for the clinical use of everolimus.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany. markus.rothenburger@novartis.com
authors.forename: Markus
authors.initials: M
authors.lastname: Rothenburger
authors.forename: Andreas
authors.initials: A
authors.lastname: Zuckermann
authors.forename: Christoph
authors.initials: C
authors.lastname: Bara
authors.forename: Manfred
authors.initials: M
authors.lastname: Hummel
authors.forename: Martin
authors.initials: M
authors.lastname: Strüber
authors.forename: Stephan
authors.initials: S
authors.lastname: Hirt
authors.forename: Hans
authors.initials: H
authors.lastname: Lehmkuhl
mesh_terms: D000799:Angioedema / Q000139:chemically induced; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control; D004347:Drug Interactions; D016903:Drug Monitoring; D000068338:Everolimus; D006331:Heart Diseases / Q000150:complications / Q000601:surgery; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D051437:Renal Insufficiency / Q000150:complications; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012871:Skin Diseases / Q000139:chemically induced; D014184:Transplantation, Homologous; D014945:Wound Healing / Q000187:drug effects
chemical_list: D007166:Immunosuppressive Agents; D008055:Lipids; D000068338:Everolimus; D020123:Sirolimus